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Neuropathy-Induced Apoptosis: Protective
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Traumatic, infectious, metabolic, and chemical noxa to
the nervous system are the etiology of a crippling dis-
ease generally termed neuropathy. Motor disorders,
altered sensibility, and pain are the pathognomonic
traits. Cellular alterations induced by this chronic pa-
thology include mitochondrial dysfunctions that lead to
the activation of the apoptotic cascade. Energy imbal-
ance can compromise the maintenance of mitochon-
drial membrane potential, furthering the release of cyto-
chrome C and the subsequent cleavage and activation
of caspases. Chronic constriction injury (CCI) of the rat
sciatic nerve is a neuropathy model able to induce a
strong mitochondrial impairment with a consequent ap-
optotic induction. In this model, the acetylcholinester-
ase inhibitor physostigmine is administered at 0.125
mg/kg i.p. (twice per day) starting from the operation
and for 15 days after. The cholinergic activation
reduces cytosolic levels of cytochrome C, suggesting
an improved stability of the mitochondrial membrane,
and the expression level of the active caspase 3 frag-
ments (19, 16 kDa) is reduced significantly with respect
to saline treatment. Accordingly, physostigmine impairs
caspase 3 protease activity. In fact, the target of the
activated caspase 3, the 89-kDa PARP fragment, is sig-
nificantly less expressed in the ligated nerve of physo-
stigmine-treated rats, reaching levels that are compara-
ble to those in the contralateral unligated nerve. Finally,
this natural acetylcholinesterase inhibitor reduces DNA
fragmentation both in the proximal and in the distal
parts of the nerve. This protection correlates with the
induction of XIAP. Therefore, apoptosis, central to tis-
sue degeneration, is prevented by repeated physostig-
mine treatment of CCI animals. VC 2009 Wiley-Liss, Inc.
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Damage to the nervous system at peripheral, spinal,
or supraspinal sites can induce complex syndromes char-
acterized by the combination of negative symptoms or
sensory deficits, such as partial or complete loss of sensa-
tion, and positive symptoms that include dysesthesia,
paresthesia, and pain. Neuropathic pain is characterized
by areas of sensory abnormality, with sensory hypo-
and/or hypersensitivity. Allodynia and hyperalgesia may
be the dominating clinical feature. Neuropathies and the
related pain are often classified according to underlying
etiology, e.g., painful diabetic neuropathy, postherpetic
neuralgia, phantom limb pain, HIV neuropathy, central
poststroke pain, and spinal cord injury pain. Finally, neu-
ropathic syndromes are also common in cancer patients,
secondary to direct infiltration or pressure on peripheral
nerves or the central nervous system, resulting from
chemotherapy or nerve injury following operation
(Jensen et al., 2001; Hughes, 2002; Obrosova et al.,
2002; Finnerup et al., 2007).
Pathophysiological mechanisms related to neuro-
pathic disease are associated with mitochondrial dysfunc-
tions that lead to activation of the apoptotic cascade. Mi-
tochondrial membrane permeabilization causes release of
cytochrome C and the subsequent formation of a com-
plex that initiates cleavage and activation of caspases
(Dalakas et al., 2001; Andre et al., 2002; Moulder et al.,
2002; Siler-Marsiglio et al., 2004; Leinninger et al.,
2006; Melli et al., 2006).
To gain insight into the relationship between neu-
ropathy and apoptosis, we recently assessed the activation
of the apoptotic pathway in rats that had undergone
loose ligation of the sciatic nerve (CCI). With this pe-
ripheral neuropathy model, we described a nerve apo-
ptotic state that encompasses the release of the cyto-
chrome C in the cytosol, activation of caspase 3, and
fragmentation of the genome (Di Cesare Mannelli et al.,
2007). Recently, Joseph and Levine (2004) have demon-
strated that apoptotic phenomena are involved in the
neuropathic pain-related hyperalgesia, insofar as the inhi-
bition of caspases 1, 2, 3, 8, and 9 reduced hyperalgesia
in rat models of neuropathy induced by cancer or antivi-
ral chemotherapy. On the other hand, acetyl-L-carnitine
had a similar profile, showing both the antihyperalgesic
and the antiapoptotic effects in the CCI model (Di
Cesare Mannelli et al., 2007).
The plant-derived acetylcholinesterase (AChE) in-
hibitor physostigmine (also known as eserine, from e´se´re´, a
West African name for the calabar bean) is able to raise
the pain threshold, showing an antihyperalgesic effect,
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both in acute (Galeotti et al., 2003) and in chronic algic
conditions (Po¨yhia¨ et al., 1999). On the other hand, the
cholinergic level enhancement has a pivotal role in neu-
roprotection and in the inhibitory mechanism of apopto-
sis (Villaroya et al., 2007; Jiang and Zhang, 2008).
Moreover, the acetylcholine-hydrolyzing enzyme AChE
has recently been described as being overexpressed in
different cell types undergoing apoptosis induced by sev-
eral agents; protein levels and both mRNA expression
and stability are enhanced (Huang et al., 2005; Jiang and
Zhang, 2008). To study protective profile of physostig-
mine in the CCI model, we evaluated the effect of
repeated treatment with this natural AChE inhibitor on
apoptosis.
MATERIALS AND METHODS
Animals
Male Sprague-Dawley rats from Harlan-Italia (Varese,
Italy) were used. Four rats were housed per cage (size 26 3
41 cm) and placed in the experimental room for acclimatiza-
tion 24 hr before the test. The animals were fed with standard
laboratory diet and with tap water ad libitum and were kept
at 238C 6 18C with a 12-hr light/dark cycle, lights on at
7 AM. All animal manipulations were carried out according to
the European Community guidelines for animal care (DL
116/92, application of the European Communities Council
Directive of 24 November 1986; 86/609/EEC). The ethical
policy of the University of Florence conforms with the Guide
for the care and use of laboratory animals of the U.S. National
Institutes of Health (NIH Publication No. 85-23, revised
1996; University of Florence assurance No. A5278-01). All
efforts were made to minimize animal suffering and to reduce
the number of animals used.
Peripheral Rat Mononeuropathy
Neuropathy was induced according to the procedure
described by Bennett and Xie (1988). Briefly, rats were anes-
thetized with 400 mg/kg intraperitoneal (i.p.) chloral hydrate.
Under aseptic conditions, the right common sciatic nerve was
exposed at the level of the middle thigh by blunt dissection.
Proximal to the trifurcation, the nerve was carefully freed
from the surrounding connective tissue, and four chromic cat
gut ligatures (4-0; Ethicon, Norderstedt, Germany) were tied
loosely around it with about 1 mm spacing. After hemostasis
was confirmed, the incision was closed in layers. The animals
were allowed to recover from surgery and then housed one
per cage with free access to water and standard laboratory
chow.
Drug Administration
Physostigmine (eserine), gabapentin, and chloral hydrate
were purchased from Sigma (St. Louis, MO). The administra-
tion was performed intraperitoneally.
Tissue Explants
After treatment, animals were sacrificed, and the right
sciatic nerves, 1 cm upstream the ligation and the trifurcation,
were explanted. The same procedure was performed for the
left, unoperated nerve. Tissue extracted was approximately 20
mg. All the experiments were performed using the entire por-
tion of the nerve, including the ligature site, except for the
nick translation labeling assay. For this assay, portions of the
nerve approximately 1 cm upstream (proximal) and 1 cm
downstream (distal) the ligation were processed, and the nerve
fragments carrying the ligature were left out. Each experiment
was performed on a single rat nerve.
Western Blot
Tissue was homogenized in lysis buffer containing 50
mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.5%
Triton X-100, Complete Protease Inhibitor (Roche, India-
napolis, IN). The homogenate was incubated on ice for 30
min, and then the suspension was sonicated on ice using three
10-sec bursts at high intensity with a 10-sec cooling period
between each burst. The samples were centrifuged at 13,000g
for 15 min at 48C. Protein concentrations in the supernatant
were measured by bicinchoninc acid (BCA; Sigma-Aldrich
Italy) assay. Thirty micrograms of each protein extract was
separated on a 4–12% sodium dodecyl sulfate (SDS)-polyacryl-
amide gel by electrophoresis and transferred onto nitrocellu-
lose membranes (Bio-Rad Italy). Membranes were blocked
with 5% nonfat dry milk in phosphate-buffered saline (PBS)
containing 0.1% Tween 20 (TPBS) and then probed over-
night with primary antibodies [caspase 3, cytochrome C, poly
(ADP-ribose) polymerase (PARP), and X-linked inhibitor of
apoptosis protein (XIAP) antibodies (Cell Signalling, Beverly,
MA); 1:1,000 in PBST/5% milk]. After washing with PBST,
the membranes were incubated for 1 hr in PBST containing
the appropriate horseradish peroxidase-conjugated secondary
antibody (1:5,000) and again washed. ECL (Pierce, Rockford,
IL) was used to visualize the peroxidase-coated bands. Densi-
tometric analysis was performed in Scion Image software.
b-Actin normalization was performed for each sample.
Caspase 3 Enzymatic Activity
Nerve segments (20 mg each) were homogenized in
200 mM Tris-HCl buffer, pH 7.5, containing 2 M NaCl, 20
mM EDTA, and 0.2% Triton X-100 and centrifuged at
5,000g for 5 min at 48C. Protein concentrations in the super-
natants were determined as reported in the previous section.
Fifty microliters of the supernatants was incubated with 0.025
mM fluorogenic peptide caspase substrate 0.025 mM rhoda-
mine110 bis (N-CBZ-L-aspartyl-L-glutamyl-L-valyl-L-aspartic
acid amide; Z-DEVD-R110; Molecular Probes, Eugene, OR)
in a buffer containing 10 mM PIPES, pH 7.4, 10 mM
EDTA, 0.5% CHAPS, at 258C for 30 min. The amount of
cleaved substrate in each sample was measured in a 96-well
plate fluorescent spectrometer (Perkin-Elmer, Norwalk, CT;
excitation at 496 nm and emission at 520 nm). Each experi-
ment was performed in duplicate.
Cytochrome C: cytosolic fraction extraction
This procedure was performed as reported by Cervia
and coworkers (2006), with minor modifications. Briefly,
nerve tissue was homogenized in 10 mM Tris-HCl buffer
(pH 7.5), 0.3 M sucrose, 1 mM EDTA, and Complete Prote-
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ase Inhibitor (Roche). Samples were centrifuged at 10,000g
for 60 min at 48C, and the supernatants containing the cyto-
solic fraction were collected. Pellets were resuspended in a
cold buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% Triton X-100, and Complete Prote-
ase Inhibitor (Roche) and sonicated on ice with three 20-sec
bursts at high intensity, with a 10-sec cooling period between
each burst. Supernatants containing the mitochondrial fraction
were obtained by centrifugation at 10,000g (30 min, 48C).
Protein concentrations were determined as reported. Western
blot with cytochrome C oxidase subunit IV (COX IV) anti-
body was performed to verify the absence of mitochondrial
contaminants in the cytosol preparation.
DNA Fragmentation. Nick Translation Labeling
Evaluation of the DNA cleavage was performed by label-
ing DNA strand breaks using the Klenow enzyme to attach to
the biotin-tagged deoxy-nucleotiodes, as described by Gorc-
zyca et al. (1993). Sections (7 lm) obtained from paraffin-em-
bedded sciatic nerves were rehydrated and then digested with
20 lg/ml proteinase K for 20 min at room temperature (RT).
After being rinsed in TBS, endogenous peroxidases were inac-
tivated with 30% H2O2, 1:10 in methanol for 5 min at RT. Af-
ter equilibration with a 0.5 M Tris-HCl buffer, pH 8.0, con-
taining 0.5 M NaCl, 0.1 M MgCl2, sections were incubated
with reaction mix containing labeled and unlabeled deoxynu-
cleotides and Klenow enzyme (Calbiochem, La Jolla, CA) at
378C for 1.5 hr. Labeling reactions were stopped by incubating
for 5 min with 0.5 M EDTA, pH 8.0, at RT. Subsequently, a
peroxidise-streptavidin conjugate was applied for 30 min at
RT, and detection was obtained by incubation with 3,30-dia-
minobenzidine-H2O2/urea solution (15 min, RT). Sections
were then treated with 0.3% methyl green for 6 min.
Statistical Analysis
Results are expressed as means 6 SEM, and an
ANOVA was performed. Fisher’s protected least significant
difference procedure was used as post hoc comparison. P <
0.01 was considered significant. Data were analyzed in Origin
7.5 software.
RESULTS
Because the complex apoptosis signalling pathway
converges on caspase-3 activation, Figure 1 shows West-
ern blot analysis of procaspase 3 (36 kDa) and its cleaved
active fragment (19 and 16 kDa). Starting on the day of
the operation, the treatment of the CCI rats with physo-
stigmine 0.125 mg/kg intraperitoneally (i.p.) twice per
day for 15 days prevented caspase 3 cleavage (Fig. 1a) in
the ligated right sciatic nerve. The expression of the 19-
kDa and 16-kDa fragments was significantly decreased in
the right nerve after physostigmine treatment with
respect to saline-treated rats (Fig. 1b). The effect of phy-
sostigmine administration was compared with the effect
of gabapentin, an antiepileptic drug widely employed in
neuropathic pain clinical management. Gabapentin at 70
mg/kg injected i.p. twice per day for 15 days was not
able to prevent caspase 3 induction (Fig. 1a,b).
The protective effect of physostigmine on caspase 3
cleavage was confirmed by the evaluation of the caspase
catalytic activity. The cleavage of the specific fluorogenic
substrate Z-DEVD-R110 allowed us to observe a three-
fold increase in caspase 3 activity in the right nerve of
saline- and gabapentin-treated groups compared with the
physostigmine group, which showed an activity in the
right nerve similar to that of the control left nerve (Fig. 2).
Cytochrome C, a mitochondrial intermembrane
protein, released following changes in the permeability
of the mitochondrial membrane activates caspase 3. We
previously demonstrated that CCI induced a cytochrome
C release in the cytosol (Di Cesare Mannelli et al.,
2007). In agreement with our previous results, a 14-kDa
band, corresponding to cytochrome C, was detected in
the purified cytosolic fractions from the right ligated
nerve of the saline group (Fig. 3). Repeated administra-
tion of physostigmine strongly prevented this effect,
whereas gabapentin failed to reduce the cytochrome C
Fig. 1. Caspase 3 levels. a: Effects of physostigmine and gabapentin
treatment on caspase 3 (procaspase 36 kDa and cleavage products 19
and 16 kDa) expression levels in the ligated right (Ndx) and unoper-
ated left (Nsx) sciatic nerves: comparison with saline treatment. The
right nerve (Ndx) was processed with loose ligation, and the adminis-
tration of substances was performed for 15 days starting on the day of
operation. b: Densitometric analysis of Western blot showing the
mean 6 SEM from five animals. Each value is expressed as caspase-
to-b-actin level ratio. *P < 0.01, significantly different from saline-
treated rats.
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level in cytosolic fractions of the right ligated nerve (Fig.
3). Western blot analysis with anti-COX IV, a protein
belonging to the inner mitochondrial membrane, was
used to confirm separation of mitochondria from the
cytosolic fraction (data not shown).
The downstream effects of caspase 3 activation
were then evaluated by measuring the expression levels
of the 89-kDa fragment of PARP, a 116-kDa protein
known to be cleaved by active caspase 3. Figure 4 shows
the expression levels of cleaved PARP in nerves of sa-
line, physostigmine, and gabapentin groups. Only physo-
stigmine prevented PARP cleavage in the right nerve.
Hence, we examined the last event of the pro-
grammed cell death cascade, DNA fragmentation. Endo-
nuclease-related gene disruption generates free 30-OH
groups at the ends of DNA fragments, which were
revealed by colorimetric nick translation labeling tech-
nique on 7-lm paraffin-embedded tissue. As shown in
Figure 5, physostigmine significantly decreased the num-
ber of apoptotic nuclei in the right ligated nerve com-
pared with saline-treated animals. The effect of the natu-
ral AChE inhibitor is comparable both in the proximal
and in the distal region of the nerve. Gabapentin-treated
rats were not able to prevent DNA fragmentation after
neuropathy induction (Fig. 5).
Finally, to verify whether this physostigmine pro-
tective effect was mediated by the IAP (inhibitor of apo-
ptosis proteins) protein family, the levels of XIAP were
examined by Western blotting. The treatment with phy-
sostigmine up-regulated XIAP, particularly in the right
nerve (Fig. 6). On the contrary, XIAP levels after gaba-
pentin treatment were analogous in the right and left
nerves and were comparable to the levels registered in
saline group animals (Fig. 6).
Fig. 3. Cytochrome C cytosolic levels. Cytosolic fraction was
extracted and processed by Western blot with specific antibody. ECL
detection images and densitometric analysis show the effect obtained
by saline, physostigmine, and gabapentin at 15 days treatment (Ndx);
for each group, the left nerve (Nsx) was considered as control.
Quantitative analysis is reported as mean 6 SEM from five animals.
*P < 0.01, significantly different from saline-treated rats.
Fig. 4. Cleaved PARP levels. Nerve homogenate evaluation for 89-
kDa PARP fragment by immunoblot. Densitometric analysis is per-
formed for each treatment group and expressed as mean 6 SEM
from five animals. *P < 0.01, significantly different from saline-
treated rats.
Fig. 2. Caspase 3 activity. a: Catalytic activity was evaluated by
measuring the fluorescent compound rhodamine 110 Z-DEVD de-
rivative in nerve homogenate. The CCI effects (Ndx) were evaluated
with respect to nonoperated nerve (Nsx) for saline, physostigmine,
and gabapentin groups. b: Caspase 3 protease activity express as
right-to-left nerve activity ratio. All data are expressed as mean 6
SEM from five animals. *P < 0.01, significantly different from
saline-treated animals.
1874 Di Cesare Mannelli et al.
Journal of Neuroscience Research
DISCUSSION
In mammals, acetylcholinesterase is encoded by a
single gene, ACHE, that by an alternative splicing gener-
ates three distinct AChE variants, each with a different
carboxyterminal sequence: the synaptic, erythrocytic,
and readthrough AChE isoforms. The carboxy-terminal
sequences determine their homologous assembly into
AChE oligomers and their heterologous association with
noncatalytic subunits, which direct the subcellular localiza-
tion of the protein (Soreq and Seidman, 2001). AChE is
able to modulate both cell growth and cell death. It is still
not known whether the cellular distribution pattern of
AChE is the primary basis for the apoptotic functions of
this enzyme. However, specific AChE variants and distri-
butions have been observed in apoptotic cells. Jiang and
Zhang (2008) observed that the expression of synaptic
AChE was markedly increased in the perinuclear and
nuclear regions of apoptotic cells. During the late stages of
apoptosis, AChE accumulates inside the apoptotic body
with condensed chromatin (Zhang et al., 2002; Yang
et al., 2002). Enhanced AChE variant expression may
influence the expression of other group genes, including
those involved in apoptosis (Ben-Ari et al., 2006). It has
been suggested that, in the presence of apoptotic stimuli or
under stress conditions, AChE would bind with specific
partners or influence other elements. This fact may explain
why the overexpression of the synaptic AChE does not
initiate but rather enhances the sensitivity to cell death (Jin
et al., 2004). AChE also contributes to the formation of
the apoptosome during apoptosis (Park et al., 2004).
Physostigmine is an AChE inhibitor originally
extracted from calabar beans. It is licensed in many
countries as an agent for reversing the effect of drugs
and poisons causing the anticholinergic syndrome. In the
present work, we show the effect of this natural com-
pound in a model of peripheral neuropathy, a syndrome
characterized by nerve damage and nervous tissue degen-
eration, and the role of apoptosis in tissue alterations and
cell loss is widely substantiated (Dalakas et al., 2001;
Andre et al., 2002; Moulder et al., 2002; Siler-Marsiglio
et al., 2004; Leinninger et al., 2006; Melli et al., 2006;
Di Cesare Mannelli et al., 2007).
The present results show that a repeated adminis-
tration of physostigmine prevents the DNA fragmentation
in the nuclei of sciatic nerve Schwann cells. This protec-
tion from the latest effect of programmed cell death also
involves the upstream events. In fact, repeated treatment
with physostigmine decreases the efflux of cytochrome C
into the cytosol, leading to a reduction of the cytochrome
C level in this cell compartment. Park et al. (2004) dem-
onstrated that silencing AChE with siRNA blocked the
interaction between apoptotic protease activating factor 1
and cytochrome C (Park et al., 2004). Our evidence
regarding an early protective effect, the release of the
cytochrome C into the cytosol, suggests that physostig-
mine treatment allows obtaining a dual result: an AChE-
dependent apoptosis inhibition and a protective effect
resulting from increased ACh levels (Kim et al., 2008).
The drastic reduction of both the expression and
the catalytic activity of the caspase 3 is in agreement
with these results. Moreover, the prevention of forma-
Fig. 6. X-linked inhibitor of apoptosis protein (XIAP) expression
levels. Right (Ndx) and left (Nsx) nerves were homogenized and
processed by Western blot with specific antibody. ECL detection
images and densitometric analysis show the effect obtained with sa-
line, physostigmine, and gabapentin at 15 days treatment. Quantita-
tive analysis is reported as mean 6 SEM from five animals. *P <
0.01, significantly different from saline-treated rats.
Fig. 5. DNA fragmentation: nick translation labeling. Evaluation of
DNA fragmentation on 7-lm nerve sections of CCI rats. Positive
nuclei number was reported for the left nerve and for the proximal
and distal regions of the right nerve, with respect to ligation. Chronic
(15 days) saline, physostigmine, and gabapentin administration effects
were observed. Quantitative analysis was performed evaluating five
animals for each group and analyzing for each nerve six sections and
six fields per section. Mean 6 SEM of positive cells is represented.
*P < 0.01, significantly different from saline-treated rats. 8P < 0.01,
significantly different from proximal nerve part values.
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tion of the 89-kDa PARP cleavage fragment, known to
be produced by caspase 3 activity, in the physostigmine-
treated rats confirms its protective activity. To elucidate
the mechanism of physostigmine-mediated apoptosis
inhibition, we evaluated XIAP level in our neuropathy
model. After 15 days from ligation, physostigmine treat-
ment increased XIAP level in the operated nerve but
not in the contralateral one. This difference was not
showed in the control group treated with saline solution,
suggesting a XIAP role in the antiapoptotic activity of
physostigmine. On the other hand, caspase function can
be terminated by its removal from the cell using the
ubiquitin-targeted proteasome degradation machinery or
by a direct inhibition of its enzymatic activity. Salvesen
and other authors (Salvesen and Duckett, 2002; Riedl
and Shi, 2004; Vaux and Silke, 2005) have reported that
members of the inhibitor of apoptosis protein (IAP)
family are capable of both functions. In particular, for
the most intensively studied family member, XIAP, bio-
chemical and structural studies have precisely mapped
the elements of this protein required for caspase inhibi-
tion (Eckelman et al., 2006). A direct, XIAP-mediated
effect of physostigmine on caspase regulation is an in-
triguing hypothesis. Neither a protective effect on apo-
ptosis activation nor an XIAP increase was revealed after
repeated gabapentin administration at a dose fully active
against neuropathic pain. The natural AChE inhibitor
physostigmine protects the sciatic nerve from apoptotic
process during neuropathy at the same doses able to
reduce hyperalgesia, confirming a link with the anti-
hyperalgesic and antiapoptotic effect as demonstrated for
caspase inhibitors (Joseph and Levine, 2004) and for
acetyl-L-carnitine (Di Cesare Mannelli et al., 2007).
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